Chemical Component Summary

Identifiers (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione (non-preferred name)
Formula C37 H67 N O13
Molecular Weight 733.93 g/mol
Type non-polymer
Isomeric SMILES CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
InChI InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1

Chemical Details

Formal Charge 0
Atom Count 118
Chiral Atom Count 18
Chiral Atoms C10 C11 C12 C13 C2 C3 C4 C5 C6 C8 C22 C23 C24 C26 C14 C16 C17 C18
Bond Count 120
Aromatic Bond Count 0

Drug Info: DrugBank

DrugBank ID DB00199   (Stereoisomeric match)
Name Erythromycin
Groups approved
Description Erythromycin is a macrolide antibiotic produced by Streptomyces erythreus. It inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits; binding inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.  Erythromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
  • (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
  • 3''-O-demethylerythromycin
  • Abomacetin
  • Eritromicina
  • Erythromycin
  • Erythromycin A
  • Erythromycin C
  • Erythromycine
  • Erythromycinum
  • Erythromycin estolate
  • Erythromycin ethylsuccinate
  • Erythromycin gluceptate
  • Erythromycin lactobionate
  • Erythromycin phosphate
  • Erythromycin stearate
  • Erythromycin thiocyanate
Brand Names
  • Alti-erythromycin Tab 250mg USP
  • Benzamycin
  • Diomycin-ont 5mg/gm
  • E.E.S.
  • E.E.s
  • E.E.s 400
  • Ees 600 Tablets 600mg
  • Ees-200
  • Ees-200 Chewable Tbs (eryped)
  • Ees-400
  • Emycin Ect 250mg
  • Ery
  • Ery-ped
  • Ery-tab
  • Erybid
  • Eryc Delayed-release Capsules
  • Erygel
  • Erymycin Ophthalmic Ointment 5mg/g
  • Erythro-500 Tab 500mg USP
  • Erythro-EC
  • Erythro-ES
  • Erythro-ES Tab 600mg USP
  • Erythro-S
  • Erythro-base
  • Erythro-base Tab 250mg USP
  • Erythrocin Filmtab 250mg
  • Erythrocin Filmtab 500mg
  • Erythrocin I.V.
  • Erythrocin IV
  • Erythrocin Lactobionate
  • Erythrocin Liq 250
  • Erythrocin Liquid 125
  • Erythrocin Stearate
  • Erythromid Tab 250mg
  • Erythromycin
  • Erythromycin Base
  • Erythromycin Base Base
  • Erythromycin Base Filmtab
  • Erythromycin Capsules USP 250mg
  • Erythromycin Ethylsuccinate
  • Erythromycin Ethylsuccinate and Sulfisoxazole Acetyl
  • Erythromycin Ophthalmic Ointment U.S.P.
  • Erythromycin Stearate Tablets USP 250mg
  • Erythromycin and Benzoyl Peroxide
  • Erythromycin-benzoyl Peroxide
  • Erythromycine 250 Tab
  • Ilosone 250mg Pulvule 375
  • Ilosone Liquid 125mg/5ml
  • Ilosone Liquid 250mg/5ml
  • Ilotycin
  • Ilotycin Cryst Op Ont 0.5% 52
  • Ilotycin Gluceptate IV Ampoule 646 1gm
  • Novo-rythro Encap 250mg
  • Novo-rythro Estolate Cap 250mg
  • Novo-rythro Estolate Suspension
  • Novo-rythro Ethylsuccinate Pwr 400mg/5ml
  • Novo-rythro Ethylsuccinate Pws
  • Novo-rythro Stearate Tab 250mg
  • Nu-erythromycin-S 250mg Tablets
  • Odan-erythromycin
  • Onguent Ophtalmique D'erythromycine USP
  • Pce
  • Pdp-erythromycin
  • Pediazole
  • Sterile Erythromycin Lactobionate Pws 1000mg
  • Sterile Erythromycin Lactobionate Pws 500mg
  • Stievamycin Forte
  • Stievamycin Mild
  • Stievamycin Regular
  • Eryc
  • Ilosone
  • Staticin
  • T-stat
Affected Organism
  • Enteric bacteria and other eubacteria
  • Streptococcus pyogenes
  • Haemophilus influenzae
  • Staphylococcus aureus
Indication For use in the treatment of infections caused by susceptible strains of microorganisms in the following diseases: respiratory tract infections (upper and lower) of mild to moderate degree, pertussis (whooping cough), as adjunct to antitoxin in infections due to Corynebacterium diphtheriae, in the treatment of infections due to Corynebacterium minutissimum, intestinal amebiasis caused by Entamoeba histolytica, acute pelvic inflammatory disease caused by Neisseria gonorrhoeae, skin and soft tissue infections of mild to moderate severity caused by Streptococcus pyogenes and Staphylococcus aureus, primary syphilis caused by Treponema pallidum, infections caused by Chlamydia trachomatis, nongonococcal urethritis caused by Ureaplasma urealyticum, and Legionnaires' disease caused by Legionella pneumophila.
Pharmacology Erythromycin is produced by a strain of Streptomyces erythraeus and belongs to the macrolide group of antibiotics. After absorption, erythromycin diffuses readily into most body fluids. In the absence of meningeal inflammation, low concentrations are normally achieved in the spinal fluid, but the passage of the drug across the blood-brain barrier increases in meningitis. Erythromycin is excreted in breast milk. The drug crosses the placental barrier with fetal serum drug levels reaching 5 - 20% of maternal serum concentrations. Erythromycin is not removed by peritoneal dialysis or hemodialysis.
Mechanism of action Erythromycin acts by penetrating the bacterial cell membrane and reversibly binding to the 50 S subunit of bacterial ribosomes or near the “P” or donor site so that binding of tRNA (transfer RNA) to the donor site is blocked. Translocation of peptides from the “A” or acceptor site to the “P” or donor site is prevented, and subsequent protein synthesis is inhibited. Erythromycin is effective only against actively dividing organisms. The exact mechanism by which erythmromycin reduces lesions of acne vulgaris is not fully known: however, the effect appears to be due in part to the antibacterial activity of the drug.
Route of administration
  • intravenous
  • ophthalmic
  • oral
  • topical
  • Gastrointestinal Agents
  • Anti-Bacterial Agents
  • Protein Synthesis Inhibitors
  • Macrolides
  • D10AF02
  • J01FA01
  • S01AA17
  • 08:12.12.04
  • 34:00.00
  • 52:04.04
CAS number 114-07-8
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682